TLDR Biotech aims to be your one-stop source for biotech and pharma updates - all with one daily email.

I’m always looking to make these news compilations more informative, impactful, and easy to navigate.

So if you have any feedback on what you like (or don’t), I’d love to hear from you! 📣

And if you like these newsletters and think a friend or colleague would benefit, please share this with them! ♻️

(You can also reach out to me on LinkedIn)

MINOR HOUSEKEEPING
How these updates are formatted

The newsletter is split into three main sections:

• THE GOOD - good news (eg. fundraises, product approvals)

• THE BAD - negative news (eg. clinical trial failures, layoffs)

• THE UGLY - negative but atypical news (lawsuits, product recalls, scandals)

Within each of the three above parts, there are additional sections for easier navigation:

• Eg. There will be multiple “The Good” sections covering things like Fundraises, Approvals, Partnerships etc.

• There will be also additional tags within these sections (Eg. fundraises may mention Stage, product approvals may mention drug name and disease area.)

See something you want to get into further? Click the Read More (goes out to either a news article or a press release).

One last thing; I know paywalls can be annoying, so there’s a [Paywall] tag for any news stories behind one.

THE GOOD
Approvals & Labels

Eli Lilly’s Alzheimer’s drug lands FDA approval
Monoclonal antibody, Alzheimer’s - Read more

Valneva’s chikungunya vaccine receives EMA approval
Vaccine, chikungunya virus - Read more

Checkpoint Therapeutics goes for BLA submission round 2
Monoclonal antibody, squamous cell carcinoma - Read more

THE GOOD
Business Development

Eggs in one basket? Samsung Biologics lands massive $1B contract from undisclosed suitor; equivalent to 40% of 2023 revenue
CDMO, manufacturing, biologics - Read more

Emergent BioSolutions lands $250M in HHS federal contract modifications
Medical countermeasures, smallpox, anthrax, botulism - Read more

Moderna gains $176M BARDA contract to speed up bird flu vaccine development
mRNA vaccine, bird flu, avian flu - Read more

Crosswalk Therapeutics bags AAV assets from former Takeda, Codexis collab
AAV gene therapy, Fabry disease, Pompe disease - Read more

Yuhan gains global rights to Ubix Pharma asset
Ubix receives ₩5B ($3.6M) upfront, ₩150B ($108M) biobucks
Small molecule, prostrate cancer - Read more

DRI Healthcare secures larger royalty stake in HLS Therapeutics recombinant protein
HLS receives US$13.25M, up to US$32.5M performance milestones
Recombinant protein, acid sphingomyelinase deficiency, Niemann-Pick disease - Read more

THE GOOD
Clinical Trials

J&J, Legend Biotech’s touts stellar Ph3 Carvykti data, overall survival
CAR-T cell therapy, multiple myeloma, cancer - Read more

Annovis Bio skyrockets on positive Ph3 Parkinson’s results
Small molecule, Parkinson’s disease - Read more

Innovent Biologics showcases Ph1 adenocarcinoma data
Antibody-drug conjugate, advanced gastric/gastroesophageal junction adenocarcinoma - Read more

Rural counties could be a great fit for decentralized clinical trials; report - Read more

THE GOOD
Criminal Acts

Mylan and its former president no longer “subject[s] of interest” in DOJ-led price-fixing probe
Price-fixing, generics - Read more

THE GOOD
Fundraises

Anbogen Therapeutics $7.5M Series A+
Small molecule, colorectal cancer - Read more

Rejuvenate Bio $4M grant from CIRM (California Institute of Regenerative Medicine)
Gene therapy, desmoplakin gene variant arrhythmogenic cardiomyopathy - Read more

THE GOOD
Marketing

In survey associating pharma companies to weight-loss drugs, Americans named Pfizer and AstraZeneca ahead of Eli Lilly and Novo Nordisk - despite the former two having no approved weight-loss meds (yet) - Read more

THE GOOD
Partnerships

Ipsen and Exelixis expand licensing and collab agreement
Small molecule, pancreatic cancer - Read more

Merck & Co.’s oncology trail platform partnership with N-Power Medicine
Clinical trial management, CRO - Read more

THE GOOD
Product Launches

Fortrea’s new AI-driven clinical trial arm
CRO, clinical trial manager, AI, machine learning - Read more

THE GOOD
Research

Gain Therapeutics Parkinson’s asset gains some pre-clinical positive buzz; mouse models
Small molecule, Parkinson’s - Read more

THE GOOD
Strategic Plans

Sumitomo Pharma CEO discusses business and product strategy
Small molecule, antipsychotic, Parkinson’s, diabetes - Read more

ENJOYING THESE NEWSLETTERS?
Consider an optional paid subscription.

It’s a lot of work to put together a daily newsletter, and it’s currently just me writing these things (+ one part-time contractor - no fancy editing team!).

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

THE BAD
Clinical Trials

Cartesian Therapeutics Ph2b hits primary endpoint…after they moved the endpoint in May
mRNA CAR-T cell therapy, generalised myasthenia gravis - Read more

THE BAD
Layoffs

Merck KGaA’s EMD Serono to lay off unspecified number of roles - Read more*

*Covered the Takeda lay offs in yesterday’s newsletter

THE BAD
Politics & Policy

Though Biosecure Act future uncertain, Chinese industry partner perception tarnished; survey
Outsourcing partnerships, CDMO, CRO, geopolitics - Read more [Paywall]

President Biden, Senator Sanders call out Novo Nordisk and Eli Lilly to lower obesity med prices
GLP-1, obesity, diabetes, weight loss - Read more

THE UGLY
Criminal Acts

Safe Chain not so safe from criminal indictment regarding counterfeit HIV medication
Counterfeit drugs, fraud - Read more

THE UGLY
Lawsuits

Pfizer, BioNTech v Moderna patent case handed mixed ruling in UK court
Covid-19 vaccine tech, pharma patent - Read more

OptumRx $20M settlement in opioid prescription suit
Opioid epidemic, prescription drug mishandling - Read more

THE UGLY
Regulatory

FDA staffers that move to big industry are told they can’t influence the industry via lobbying *winkwink*
Private lobbying, ethics - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Want to sponsor this newsletter and reach an audience of 450+ biotech and pharma professionals? Reach us here. 👍

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.